Etiometry develops decision‑support software for intensive care clinicians that aggregates vital signs from multiple sources into a single platform to surface evolving clinical risk. The company’s tools are used in more than 20 of the top U.S. children’s hospitals and have been adopted in several adult ICUs at leading U.S. medical centers. Etiometry has obtained multiple FDA 510(k) clearances (six as of 2020) and anticipated a seventh clearance in the second half of 2021 for new risk algorithms. Founded in 2010 and operating out of Boston, the company emphasizes building clinical evidence and refining the predictive models that power its software. Future plans described in the articles include extending use of the platform to other hospital care settings, accelerating R&D, and expanding clinical initiatives and commercial reach. The company recently expanded its leadership team to support scaling sales, strategy, and finance functions.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2021